Suppr超能文献

冠状动脉钙化进展在指导冠心病事件风险患者管理中的潜在应用。

Potential use of coronary artery calcium progression to guide the management of patients at risk for coronary artery disease events.

作者信息

McEvoy John W, Blaha Michael J, Nasir Khurram, Blumenthal Roger S, Jones Steven R

机构信息

Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Blalock 524C, 600 N Wolfe St, Baltimore, MD, 21287, USA,

出版信息

Curr Treat Options Cardiovasc Med. 2012 Feb;14(1):69-80. doi: 10.1007/s11936-011-0154-5.

Abstract

Subclinical coronary artery disease (CAD) is widespread and under-diagnosed. Preventive efforts are required to reduce the burden of this disease and its complications. Imaging of coronary artery calcium (CAC) with cardiac computed tomography is highly specific for the diagnosis of subclinical CAD and can also facilitate treatment decisions in preventive cardiology. Indeed, CAC testing has been recommended by the American Heart Association for asymptomatic patients at intermediate risk for future cardiac events (as defined by clinical risk factors) to refine existing risk estimates. However, the optimal follow-up of those patients who have already undergone CAC testing remains unclear, particularly with regards to repeat CAC testing. The existing literature points to two major considerations for the use of CAC progression in the management of subclinical CAD. On one hand, CAC progression has been used as a surrogate marker to test the efficacy of cardiac preventive medications in halting or regressing CAD. To date, study results have been mostly disappointing and CAC progression appears resistant to medications such as statins. On the other hand, however, CAC progression has potential as a clinical indicator of underlying CAD activity. This may facilitate optimization or up-titration of preventive medications by using CAC progression as a marker of subclinical disease activity. We believe that the data, thus far, argues against the use of a CAC progression as a clinical surrogate marker of preventive therapy efficacy. Further studies with non-statin medications and with concomitant outcome data are needed. However, CAC progression has potential for monitoring subclinical CAD in some patients and may facilitate treatment decisions. In this review we will provide recommendations for repeat CAC testing and discuss when repeat CAC testing may be helpful to assess coronary artery disease progression.

摘要

亚临床冠状动脉疾病(CAD)广泛存在且诊断不足。需要采取预防措施来减轻这种疾病及其并发症的负担。心脏计算机断层扫描对冠状动脉钙化(CAC)进行成像,对亚临床CAD的诊断具有高度特异性,并且还可以为预防性心脏病学中的治疗决策提供便利。事实上,美国心脏协会已建议对未来心脏事件处于中度风险(由临床风险因素定义)的无症状患者进行CAC检测,以完善现有的风险评估。然而,对于已经进行过CAC检测的患者,最佳的随访方案仍不明确,尤其是关于重复进行CAC检测方面。现有文献指出,在亚临床CAD的管理中使用CAC进展有两个主要考虑因素。一方面,CAC进展已被用作替代指标,以测试心脏预防性药物在阻止或逆转CAD方面的疗效。迄今为止,研究结果大多令人失望,而且CAC进展似乎对他汀类药物等药物有抗性。另一方面,然而,CAC进展有可能作为潜在CAD活动的临床指标。这可能通过将CAC进展用作亚临床疾病活动的标志物来促进预防性药物的优化或增加剂量。我们认为,迄今为止的数据反对将CAC进展用作预防性治疗疗效的临床替代指标。需要对非他汀类药物以及伴随的结果数据进行进一步研究。然而,CAC进展在监测某些患者的亚临床CAD方面具有潜力,并且可能有助于治疗决策。在本综述中,我们将提供重复进行CAC检测的建议,并讨论重复进行CAC检测何时可能有助于评估冠状动脉疾病的进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验